Lourdes
Calvo Martínez
![Foto de Lourdes](/img/nophoto.png)
![Foto de Queen Mary University of London](/img/noimage_org.png)
Queen Mary University of London
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de Queen Mary University of London (2)
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394